Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Lipocine Inc. | LPCN 1148 | Liver cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopenia | Phase 2 | Data Released | Oral | Gastroenterology |
| Lipocine Inc. | LPCN 1144 - (LiFT) | Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH) | Phase 2 | Looking for Funding | Oral | Gastroenterology |
| Liquidia Corporation | L606 (liposomal treprostinil) | Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) | Phase 3 | Enrollment Initiation | Inhalation | Cardiology |
| Lisata Therapeutics Inc. | LSTA1 in combination with gemcitabine and nab-paclitaxel - (ASCEND) | 1L metastatic pancreatic ductal adenocarcinoma | Phase 2b | Data Released | Intravenous | Oncology |
| Lisata Therapeutics Inc. | XOWNA (CLBS16) - (FREEDOM) | Coronary microvascular dysfunction (CMD) | Phase 2b | Trial Discontinued | Intracoronary infusion | Cardiology |
| Lisata Therapeutics Inc. | HONEDRA (CLBS12) | Critical Limb Ischemia (CLI) | Phase 2 | Trial Discontinued | Intramuscular injection | Cardiology |
| Lisata Therapeutics Inc. | CLBS03 (The Sanford Project T-Rex Study) | Type 1 diabetes | Phase 2 | Trial Discontinued | Intravenous | Endocrinology |
| Lisata Therapeutics Inc. | LSTA1 (CEND-1) with Atezolizumab (Tecentriq) | Metastatic pancreatic ductal adenocarcinoma (mPDAC) | Phase 2 | Enrollment Initiation | Intravenous | Oncology |
